Organon's first quarter results prompted a significant negative market reaction, despite earnings coming in above Wall Street expectations. Management pointed to ongoing pricing pressure, the loss of exclusivity for key cardiovascular drugs, and increased commercial investment in recently acquired assets as primary factors behind the year-over-year revenue decline and operating margin compression. CEO Kevin Ali described the environment as "volatile" and acknowledged that external uncertainty, alongside internal restructuring, shaped the quarter's performance. While products like Nexplanon and Vtama showed growth, overall results reflected headwinds across legacy brands and regional markets.
Is now the time to buy OGN? Find out in our full research report (it’s free).
Organon (OGN) Q1 CY2025 Highlights:
- Revenue: $1.51 billion vs analyst estimates of $1.5 billion (6.7% year-on-year decline, 0.6% beat)
- Adjusted EPS: $1.02 vs analyst estimates of $0.89 (14.2% beat)
- Adjusted EBITDA: $484 million vs analyst estimates of $458.6 million (32% margin, 5.5% beat)
- Operating Margin: 15.4%, down from 23.2% in the same quarter last year
- Market Capitalization: $2.6 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions Organon’s Q1 Earnings Call
-
David Amsellem (Piper Sandler) pressed management on confidence in Vtama’s sales target and payer access. CEO Kevin Ali emphasized managed care progress and positive physician feedback as reasons for confidence, highlighting ongoing improvements in coverage.
-
Michael Nedelcovych (TD Cowen) asked whether future business development would focus on more frequent or larger deals, and how broad Organon’s definition of women’s health would be. Ali explained the company’s flexible approach, noting a willingness to pursue assets outside traditional categories if they fit strategic and financial criteria.
-
Ethan Brown (JPMorgan) inquired about the role of share repurchases and the impact of potential future tariffs. CFO Matt Walsh clarified that leverage reduction supersedes share buybacks and stated that tariff risks are currently minimal but subject to change.
-
Umer Raffat (Evercore ISI) challenged the consistency of Organon’s capital allocation priorities, referencing the abrupt dividend reset. Ali cited investor sentiment and external volatility as drivers for the change, reiterating the focus on deleveraging.
-
Bhavin Patel (Bank of America) questioned the risk of generic competition for Nexplanon and the breakdown of one-time costs. Management responded that patent protections and regulatory barriers remain strong, and that most one-time costs are tied to manufacturing separation and restructuring.
Catalysts in Upcoming Quarters
In upcoming quarters, our analysts will monitor (1) the pace of uptake and payer access for Vtama in both U.S. and planned international launches, (2) progress on achieving operating expense savings from restructuring efforts, and (3) the trajectory of Nexplanon’s sales, especially as the five-year indication approaches potential approval. We are also attentive to any shifts in tariff policy or regulatory developments that could impact manufacturing and market access.
Organon currently trades at $9.90, down from $12.91 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.
While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.